SM

Sandeep Meer

Active Director Director DIN 10678445
DIN 10678445 First appointment Jun 2024 Primary industry Paper
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2024
Shareholding value •••• Premium profile

About Sandeep Meer

Data last updated:

Sandeep Meer is a Director at Cilead Pharmaceuticals Private Limited (since 2024). The company operates in Paper. Cilead Pharmaceuticals Private Limited reported revenue of ₹8.5 Lakh (FY 2025).

DIN 10678445
Primary Designation Director
Industry Paper
First Appointment 23 Jun 2024
Oldest Company Age 2 yrs
Largest company Cilead Pharmaceuticals Private Limited · ₹8.5 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director23 Jun 20242024₹8.5 Lakh (FY 2025)Active

Board colleagues of Sandeep Meer

NameDINCompanyDesignation
Monika Meer10678444Cilead Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Cilead Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sandeep Meer

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sandeep Meer

Sandeep Meer currently holds 1 directorship: Cilead Pharmaceuticals Private Limited (Director, since 23 Jun 2024, revenue ₹8.5 Lakh (FY 2025)).

Sandeep Meer was first appointed on 23 Jun 2024 as Director at Cilead Pharmaceuticals Private Limited.

The current boards of Sandeep Meer's companies include Monika Meer (Cilead Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available